Skip to main content
. 2017 Sep 14;129(23):879–892. doi: 10.1007/s00508-017-1248-1

Table 4.

Treatment targets that were met 5 years after study inclusion in Austrian patients with stable CAD (N, [%])h

Variable Patients with stable CAD (N = 305)
Normalized blood pressurea 134/229 (58.5)
Lowered LDL cholesterol 1b 138/196 (70.4)
Lowered LDL cholesterol 2c 48/196 (24.5)
Lowered HbA1c 1d 33/77 (42.9)
Lowered HbA1c 2e 20/77 (26.0)
HR ≤ 60 bpmf 3/7 (42.9)
Smoking cessationg 16/38 (42.1)

bpm beats per minute, HbA1c glycated hemoglobin, HR heart rate, LDL low-density lipoprotein, N number of patients

ain treated hypertensive patients, defined as systolic blood pressure <140 mm Hg, diastolic blood pressure <90 mm Hg

bin patients with dyslipidaemia at baseline, defined as LDL cholesterol plasma level <1.0 g/l or 2.6 mmol/l

cin patients with dyslipidaemia at baseline, defined as LDL cholesterol plasma level <0.7 g/l or 1.8 mmol/l

din diabetic patients, defined as HbAc1 level <7.0%

ein diabetic patients, defined as HbAc1 level <6.5%

fin patients with anginal symptoms

gfor current smokers at baseline

hpercentages are of the data available